• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Complera is a single tablet fixed dose comprised of emtricitabine, tenofovir disoproxil fumarate and rilpivirine. Emtricitabine and tenofovir are nucleoside reverse transcriptase inhibitors and rilpivirine is a non-nucleoside reverse transcriptase inhibitor.

    Complera is specifically approved for the treatment of HIV-1 infection in antiretroviral treatment-naive adults.

    Complera is supplied as a tablet for oral administration. Each tablet contains 200 mg of emtricitabine, 27.5 mg of rilpivirine hydrochloride and 300 mg of tenofovir disoproxil fumarate. The recommended dose is one tablet taken orally once daily with a meal.

    Clinical Results

    FDA Approval
    The FDA approval of Complera was based on 48-week data from two phase III double-blind, active controlled, randomized studies (ECHO and THRIVE) conducted by Tibotec that evaluated the safety and efficacy of rilpivirine compared to efavirenz (EFV) among treatment-naïve HIV-1 infected adults. Both arms of the study were administered with a background regimen, in which the majority of subjects in the rilpivirine arm received Truvada. Both trials reached their primary objective, the non-inferiority of rilpivirine vs. EFV in the proportion of patients achieving an undetectable viral load (less than 50 copies/mL) at week 48 (with a maximum allowable difference of 12%). Results showed that 84.3% of patients in the rilpivirine group reached an undetectable viral load, compared with 82.3% of patients in the EFV group. The virologic failure rate was 9% in the rilpivirine group and 4.8% in the EFV group. The pooled analysis at 96 weeks showed that 78% of subjects achieved and sustained an undetectable plasma viral load. These data demonstrated non-inferiority (12% margin) of rilpivirine to EFV in lowering viral load in this population at 96 weeks. Subjects taking rilpivirine had a virologic failure rate of 14% compared to 8% experienced by subjects taking EFV, of which 3 percent and 2 percent occurred in the second year of treatment, respectively. A bioequivalence study, conducted by Gilead, demonstrated that the co-formulated single-tablet regimen achieved the same levels of medication in the blood as emtricitabine plus rilpivirine plus tenofovir disoproxil fumarate.

    Side Effects

    Adverse events associated with the use of Complera may include, but are not limited to, the following:
    rilpivirine

    • insomnia
    • headache

    emtricitabine and tenofovir disoproxil fumarate
    • diarrhea
    • nausea
    • fatigue
    • headache
    • dizziness
    • depression
    • insomnia
    • abnormal dreams
    • rash

    Mechanism of Action

    Complera is a single tablet fixed dose comprised of emtricitabine, tenofovir disoproxil fumarate and rilpivirine. Emtricitabine and tenofovir are nucleoside reverse transcriptase inhibitors and rilpivirine is a non-nucleoside reverse transcriptase inhibitor.

    Literature References

    Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. The Lancet 2011 Jul 16;378(9787):238-46

    Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K; THRIVE study group Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. The Lancet 2011 Jul 16;378(9787):229-37

    Additional Information

    For additional information regarding Complera or HIV, please visit the Complera web page.

    Company Name: Gilead
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    • VaccinewithNeedle-360x240.png

      2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

    • Dominate-360x240.png

      COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing